years, clinical follow-up or death occurred in 95.5% (968/1014) of the patients. The 2-year rate of TVF was 10.4% (101/972), of which 6.4% (62/972) was considered related to the study stent. Cardiac death was 1.7% (7987), with 0.2% considered related to the study stent. Target vessel-related MI was 1.7% (17972) (1.5% study stent-related), and TVR was 8.3% (81972) (5.7% study stent-related). ARC definite/probable ST was 1.0% (10972), with 0.9% (9792) considered related to the study stent. Two-year outcomes for subsets, including small vessels, long lesions, and diabetes, will be available at the meeting.

Conclusions: At 2 years post-procedure, the thin-strut, platinum chromium, paclitaxel-eluting TAXUS Element stent continues to demonstrate good performance and safety in everyday clinical practice.

TCT-P581
Long-term Patient-related and Stent-related Outcomes of Second-Generation Everolimus-Eluting Xience V Stents versus Zotarolimus-Eluting Resolute Stents in Real-World Practice: Three Year Results From the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries
Joo Myung Lee1, Kyung Woo Park1, Jung-Kyun Han1, Han-Mo Yang2, Hyeon-Jae Kang1, Bon-Kwon Koo3, Hun Cheol Lee4, Sung-II Woo5, Jin Sik Park6, Dong-Woon Ju6, Dong Woon Jeon7, Seok-Kyu Oh8, Jong Seon Park9, Doo-II Kim10, Mary Andrade11, Danyoung Kim12, M. Teo13, Tae Young Kim14, Hye-Yoo Kim6,11Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Korea, Republic of, 1Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Korea, Republic of, 2Pusan National University Hospital, Busan, Korea, Republic of, 3Inha University hospital, incheon, Korea, Republic of, 4Sejong General Hospital, Bucheon, Korea, Republic of, 5Sejong University Hospital, Cheonan, Korea, Republic of, 6NHIC Ilan hospital, Koyung, Korea, Republic of, 7Wonkwang University hospital, Iksan, Korea, Republic of, 8Yeungnam University Medical Center, Dae gu, Korea, Republic of, 9Inje University Haemundae Paik Hospital, Busan, Korea, Republic of, 10Soonchunhyang University Hospital, Seoul, Korea, Republic of, 11Uijeongbu St Mary’s Hospital, Uijeongbu, Korea, Republic of, 12Korea University Anam Hospital, Seoul, Korea, Republic of, 13Gachon University Gil Hospital, Incheon, South Korea, Republic of, 14Hospital de Sant Pau y Santa Creu, Barcelona, Spain

Background: Limited clinical data is available in patients who underwent percutaneous coronary intervention (PCI) with drug eluting stents in very small vessels (reference vessel diameter [RVD] < 2.25 mm). Methods: We examined the clinical outcomes of patients who underwent PCI using ResoluteTM zotarolimus-eluting stent (R-ZES) in the pooled RESOLUTE program in vessels with RVD ≤ 2.25 mm and compared them to those of patients with RVD > 2.25 but ≤ 2.75 mm. The RESOLUTE global clinical program includes: RESOLUTE First-in-Human, RESOLUTE All Comers (R-AC), RESOLUTE International, RESOLUTE US, RESOLUTE Japan, RESOLUTE Japan Small Vessel, RESOLUTE Asia, RESOLUTE China, and Resolute China Registry. Target Lesion Failure (TLF) was the composite of death from cardiac causes, target vessel myocardial infarction (TV-MI), and target lesion revascularization (TLR). The incidence of clinical events was calculated using the Kaplan Meier. Given differences in baseline characteristics, patients were matched by propensity scores based on 24 baseline variables and adjusted p-values are provided. Results: A total of 1203 subjects with RVD ≤ 2.25 mm RVD and 2773 subjects with RVD > 2.25 but ≤ 2.75 mm were treated with R-ZES. Compared with patients with RVD > 2.25 but ≤ 2.75 mm, patients with RVD < 2.25 mm had more complex baseline characteristics including prior PCI (33% vs. 26%, p < 0.001) and history of hypertension (78% vs. 72%, p < 0.001), respectively. However, there was no significant difference in TLR, TLF, CD/TM-MI or ARC definite/probable ST at 3 years (Table).

Conclusions: No increased risk is associated with the use of R-ZES in very small vessels (RVD ≤ 2.25 mm) compared with use in small vessels between 2.25 and 2.75 mm. Low rates of clinical events were observed through long-term follow-up in both groups. Submitted on behalf of the RESOLUTE Global Clinical Program

TCT-P583
Longest available clinical follow-up of a cohort of “real-world” patients treated exclusively with drug-eluting stents: Results of 12 years of the DESIRE (Drug-Eluting Stents In the Real world) Registry
Jose d Costa Jf1, Amanda Sousa1, Adriana Moreira1, RICARDO A. COSTA4, Manuel N. Cano1, Galo Maldonado1, cantidio campos neto6, Lucas P. Damiani7, Diniyri A. Siqueira1, I. Eduardo Sousa1, 1Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil, 2Dante Pazzanese, São Paulo, Brazil, 3HCor, São Paulo, Brazil, 4HCor, São Paulo, Brazil, 5Hospital do Coração - Associação do Sanatório Sírio, São Paulo, Brazil, 6Dante Pazzanese Institute of Cardiology, São Paulo, Brazil, 7Instituto Dante Pazzanese de Cardiologia, São Paulo, CA

Background: There is still uncertainty about the durability of the results of drug-eluting stents (DES) in real-world complex patients. We sought to provide the longest clinical follow-up data on outcomes of unselected patients treated solely with DES.

Methods: The DESIRE registry is a prospective, single-center registry encompassing all consecutive patients treated solely with DES since May 2002. The primary goal is the very long-term occurrence of MACE and stent thrombosis (ST). Patients were clinically followed at 1, 6 and 12 months and then annually. A multivariate model was built to determine independent predictors of MACE, TLR and ST.

Results: A total of 5,500 patients were included. The mean age was 64 ± 11 years. DM was detected in 29.7% and 44.8% presented with acute coronary syndrome. SVG treatment of SVG (HR 1.63; 95% CI, 1.22 to 2.18, p < 0.001) and patient related outcomes, respectively) . The rate of de novo or probable stent thrombosis at 3 years (22 [0.7%] vs. 10 [0.5%], p = 0.370) was also similar. The strongest predictors of target lesion failure at 3-year follow-up were chronic renal failure (adjusted HR 3.615, 95% CI 2.440-5.354, p < 0.001) and renal insufficiency (1.5; 95% CI, 1.34 to 1.87, p < 0.001), multivessel disease (HR 1,63; 95% CI, 1.22 to 2.18, p < 0.001), multivessel disease (HR 1.39; 95% CI, 1.03 to 1.87, p < 0.004). Independent predictors of ST were PCI for STEMI (HR 0.92, 95% CI 0.70-1.20, p = 0.812) and the patient-related outcome (420 [13.7%] vs. 221 [7.3%], p = 0.006). Multivariate analysis, chronic renal failure (adjusted HR 3.615, 95% CI 2.440-5.354, p < 0.001) and off-label indication (adjusted HR 1.782, 95% CI 1.169-2.718, p = 0.007) were the strongest predictors of target lesion failure at 3-year.

Conclusions: In this robust real world registry with unrestricted use of EES and ZES-R, both stents showed comparable safety and efficacy at 3-year follow-up. Overall incidences of target lesion failure and definite stent thrombosis, including very late stent thrombosis, were low, even in the patients with off label indications, suggesting excellent long term safety and sustained efficacy of both types of second generation DES.

TCT-S82
Percutaneous Coronary Intervention of Very Small Vessels in the RESOLUTE Global Clinical Program
Antonio Serra1,2
1Hospital de Sant Pau y Santa Creu, Barcelona, Spain

Background: Limited clinical data is available in patients who underwent percutaneous coronary intervention (PCI) with drug eluting stents in very small vessels (reference vessel diameter [RVD] ≤ 2.25 mm).

Methods: We examined the clinical outcomes of patients who underwent PCI using ResoluteTM zotarolimus-eluting stent (R-ZES) in the pooled RESOLUTE program in vessels with RVD ≤ 2.25 mm and compared them to those of patients with RVD > 2.25 but ≤ 2.75 mm. The RESOLUTE global clinical program includes: RESOLUTE First-in-Human, RESOLUTE All Comers (R-AC), RESOLUTE International, RESOLUTE US, RESOLUTE Japan, RESOLUTE Japan Small Vessel, RESOLUTE Asia, RESOLUTE China, and Resolute China Registry. Target Lesion Failure (TLF) was the composite of death from cardiac causes, target vessel myocardial infarction (TV-MI), and target lesion revascularization (TLR). The incidence of clinical events was calculated using the Kaplan Meier. Differences in baseline characteristics, patients were matched by propensity scores based on 24 baseline variables and adjusted p-values are provided.

Results: A total of 1203 subjects with RVD ≤ 2.25 mm RVD and 2773 subjects with RVD > 2.25 but ≤ 2.75 mm were treated with R-ZES. Compared with patients with RVD > 2.25 but ≤ 2.75 mm, patients with RVD < 2.25 mm had more complex baseline characteristics including prior PCI (33% vs. 26%, p < 0.001) and history of hypertension (78% vs. 72%, p < 0.001), respectively. However, there was no significant difference in TLR, TLF, CD/TM-MI or ARC definite/probable ST at 3 years (Table).

Conclusions: No increased risk is associated with the use of R-ZES in very small vessels (RVD ≤ 2.25 mm) compared with use in small vessels between 2.25 and 2.75 mm. Low rates of clinical events were observed through long-term follow-up in both groups. Submitted on behalf of the RESOLUTE Global Clinical Program